Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of bimekizumab in moderate to severe hidradenitis suppurativa
2020-004179-42Phase 3Active
- Sponsor
- UCB
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in hidradenitis suppurativa (HS), sponsored by UCB. Primary endpoint: Percentage of participants with treatment-emergent adverse events. Started Feb 2021; status: active.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2020-004179-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004179-42.